Literature DB >> 22964246

In vitro antifungal activity of isavuconazole against Madurella mycetomatis.

Wendy Kloezen1, Jacques F Meis, Ilse Curfs-Breuker, Ahmed H Fahal, Wendy W J van de Sande.   

Abstract

Currently, therapy of black-grain mycetoma caused by Madurella mycetomatis consists of extensive debridement of the infected tissue combined with prolonged antifungal therapy with ketoconazole or itraconazole. In the present study, the in vitro activity of the new triazole isavuconazole toward M. mycetomatis was evaluated. Isavuconazole appeared to have high activity against M. mycetomatis, with MICs ranging from ≤0.016 to 0.125 μg/ml. Due to its favorable pharmacokinetics, isavuconazole could be a promising antifungal agent in the treatment of mycetoma.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22964246      PMCID： PMC3486573          DOI： 10.1128/AAC.01170-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

Authors:  Shivaprakash M Rudramurthy; Arunaloke Chakrabarti; Erik Geertsen; Johan W Mouton; Jacques F Meis
Journal:  Diagn Microbiol Infect Dis       Date:  2011-09-19       Impact factor: 2.803

2.  In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.

Authors:  M R Shivaprakash; Erik Geertsen; Arunaloke Chakrabarti; Johan W Mouton; Jacques F Meis
Journal:  Mycoses       Date:  2011-04-25       Impact factor: 4.377

3.  Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method.

Authors:  Wendy W J van de Sande; Ad Luijendijk; Abdalla O A Ahmed; Irma A J M Bakker-Woudenberg; Alex van Belkum
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Genotyping of Madurella mycetomatis by selective amplification of restriction fragments (amplified fragment length polymorphism) and subtype correlation with geographical origin and lesion size.

Authors:  Wendy W J van de Sande; Roy Gorkink; Guus Simons; Alewijn Ott; Abdalla O A Ahmed; Henri Verbrugh; Alex van Belkum
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species.

Authors:  Michaela Lackner; G Sybren de Hoog; Paul E Verweij; Mohammad J Najafzadeh; Ilse Curfs-Breuker; Corné H Klaassen; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

6.  In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine.

Authors:  Alex van Belkum; Ahmed H Fahal; Wendy W J van de Sande
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

7.  Development of a species-specific PCR-restriction fragment length polymorphism analysis procedure for identification of Madurella mycetomatis.

Authors:  A O Ahmed; M M Mukhtar; M Kools-Sijmons; A H Fahal; S de Hoog; B G van den Ende; E E Zijlstra; H Verbrugh; E S Abugroun; A M Elhassan; A van Belkum
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

Review 8.  Mycetoma caused by Madurella mycetomatis: a neglected infectious burden.

Authors:  Abdalla O A Ahmed; Willem van Leeuwen; Ahmed Fahal; Wendy van de Sande; Henri Verbrugh; Alex van Belkum
Journal:  Lancet Infect Dis       Date:  2004-09       Impact factor: 25.071

9.  In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay.

Authors:  Abdalla O A Ahmed; Wendy W J van de Sande; Wim van Vianen; Alex van Belkum; Ahmed H Fahal; Henri A Verbrugh; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

10.  Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Markus Heep; Michael Schleimer; Erhard Weidekamm; Tom Brown; Michael Roehrle; Christoph Beglinger
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938
View more
  16 in total

1.  Pyomelanin Secretion in Madurella mycetomatis Interferes with Spectrophotometric Endpoint Reading Using the Sensititre YeastOne alamarBlue Assay but Not with Visual Endpoint Reading.

Authors:  B Nyuykonge; P D Croughs; A H Fahal; A Verbon; W W J van de Sande
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  In vitro susceptibility testing for black grain eumycetoma causative agents.

Authors:  Wendy W J van de Sande
Journal:  Trans R Soc Trop Med Hyg       Date:  2021-04-14       Impact factor: 2.184

Review 3.  The mycetoma knowledge gap: identification of research priorities.

Authors:  Wendy W J van de Sande; El Sheikh Maghoub; Ahmed H Fahal; Michael Goodfellow; Oliverio Welsh; Ed Zijlstra
Journal:  PLoS Negl Trop Dis       Date:  2014-03-27

Review 4.  Mycetoma medical therapy.

Authors:  Oliverio Welsh; Hail Mater Al-Abdely; Mario Cesar Salinas-Carmona; Ahmed Hassan Fahal
Journal:  PLoS Negl Trop Dis       Date:  2014-10-16

Review 5.  Invasive mold infections in solid organ transplant recipients.

Authors:  Yoann Crabol; Olivier Lortholary
Journal:  Scientifica (Cairo)       Date:  2014-11-23

Review 6.  Mycetoma: An Update.

Authors:  Vineet Relhan; Khushbu Mahajan; Pooja Agarwal; Vijay Kumar Garg
Journal:  Indian J Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.494

Review 7.  Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections.

Authors:  Diego R Falci; Alessandro C Pasqualotto
Journal:  Infect Drug Resist       Date:  2013-10-22       Impact factor: 4.003

8.  Madurella mycetomatis is highly susceptible to ravuconazole.

Authors:  Sarah Abdalla Ahmed; Wendy Kloezen; Frederick Duncanson; Ed E Zijlstra; G Sybren de Hoog; Ahmed H Fahal; Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2014-06-19

9.  The combination of amoxicillin-clavulanic acid and ketoconazole in the treatment of Madurella mycetomatis eumycetoma and Staphylococcus aureus co-infection.

Authors:  Najwa A Mhmoud; Ahmed Hassan Fahal; El Sheikh Mahgoub; Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2014-06-19

10.  The in vitro antifungal activity of sudanese medicinal plants against Madurella mycetomatis, the eumycetoma major causative agent.

Authors:  Hassabelrasoul Elfadil; Ahmed Fahal; Wendy Kloezen; Elhadi M Ahmed; Wendy van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2015-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.